资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医迅达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#滤泡性淋巴瘤#
69篇内容 | 2231人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=5bd36658e94, topicName=滤泡性淋巴瘤, introduction=滤泡性淋巴瘤, content=null, image=null, comments=69, allHits=2231, url=https://h5.medsci.cn/topic?id=66587, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=10568, tagList=[TagDto(tagId=10568, tagName=滤泡性淋巴瘤)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1278816, encodeId=cdbd12e88165a, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号,用以治疗滤泡性淋巴瘤(FL), objectType=article, longId=206517, objectId=375420651efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375420651efe, replyNumber=0, likeNumber=52, createdTime=2021-02-02, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375420651efe, moduleTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号,用以治疗滤泡性淋巴瘤(FL), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=375420651efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278815, encodeId=848c12e88156f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet oncol:EZH2抑制剂,有望成为滤泡性淋巴瘤患者的新选择!, objectType=article, longId=201959, objectId=fc0c201959b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc0c201959b7, replyNumber=0, likeNumber=65, createdTime=2020-10-12, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc0c201959b7, moduleTitle=Lancet oncol:EZH2抑制剂,有望成为滤泡性淋巴瘤患者的新选择!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc0c201959b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278814, encodeId=ff6112e8814fa, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤, objectType=article, longId=199989, objectId=134a199989af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134a199989af, replyNumber=0, likeNumber=59, createdTime=2020-08-29, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134a199989af, moduleTitle=Blood:维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134a199989af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278813, encodeId=c92812e881389, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=诺华CAR-T疗法Kymriah:达到滤泡性淋巴瘤试验终点, objectType=article, longId=198822, objectId=494f19882295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=494f19882295, replyNumber=0, likeNumber=48, createdTime=2020-08-07, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=494f19882295, moduleTitle=诺华CAR-T疗法Kymriah:达到滤泡性淋巴瘤试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=494f19882295)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278812, encodeId=e56712e881236, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤,获得FDA的突破性治疗指定, objectType=article, longId=197588, objectId=c63a19e588ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c63a19e588ba, replyNumber=0, likeNumber=52, createdTime=2020-07-17, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c63a19e588ba, moduleTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤,获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c63a19e588ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278811, encodeId=91a412e8811ac, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Hematol Oncol:雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达, objectType=article, longId=196148, objectId=6a1f19614846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1f19614846, replyNumber=0, likeNumber=65, createdTime=2020-06-21, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1f19614846, moduleTitle=Hematol Oncol:雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1f19614846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278810, encodeId=ce8512e88103a, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=滤泡性淋巴瘤一线治疗将有新标准!新一代抗CD20单抗佳罗华®中国获批, objectType=article, longId=194365, objectId=0d90194365fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d90194365fe, replyNumber=0, likeNumber=50, createdTime=2020-05-20, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d90194365fe, moduleTitle=滤泡性淋巴瘤一线治疗将有新标准!新一代抗CD20单抗佳罗华®中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d90194365fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278809, encodeId=107612e88091f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=AACR 2020:伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动(PERSPECTIVE研究), objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=57, createdTime=2020-05-03, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020:伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动(PERSPECTIVE研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278808, encodeId=7df712e88083f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=FDA授予Kymriah治疗滤泡性淋巴瘤再生医学高级疗法(RMAT)认定, objectType=article, longId=192833, objectId=390d19283388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=390d19283388, replyNumber=0, likeNumber=50, createdTime=2020-04-25, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=390d19283388, moduleTitle=FDA授予Kymriah治疗滤泡性淋巴瘤再生医学高级疗法(RMAT)认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=390d19283388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278807, encodeId=094112e88079f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=FDA授予Umbralisib孤儿药认定,以治疗滤泡性淋巴瘤(FL), objectType=article, longId=189499, objectId=623b18949984, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623b18949984, replyNumber=0, likeNumber=39, createdTime=2020-03-08, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623b18949984, moduleTitle=FDA授予Umbralisib孤儿药认定,以治疗滤泡性淋巴瘤(FL), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623b18949984)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278806, encodeId=58bb12e8806fb, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, objectType=article, longId=189157, objectId=3e3b18915ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e3b18915ec7, replyNumber=0, likeNumber=45, createdTime=2020-03-04, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e3b18915ec7, moduleTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e3b18915ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278805, encodeId=e97012e8805e0, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=TAZVERIK(tazemetostat)治疗滤泡性淋巴瘤:FDA已批准其NDA, objectType=article, longId=188196, objectId=741e188196b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=741e188196b9, replyNumber=0, likeNumber=40, createdTime=2020-02-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=741e188196b9, moduleTitle=TAZVERIK(tazemetostat)治疗滤泡性淋巴瘤:FDA已批准其NDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=741e188196b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278804, encodeId=b72012e880444, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:局限性和晚期滤泡性淋巴瘤的基因表达差异!, objectType=article, longId=187103, objectId=968118e10328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968118e10328, replyNumber=0, likeNumber=52, createdTime=2020-02-03, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968118e10328, moduleTitle=Blood:局限性和晚期滤泡性淋巴瘤的基因表达差异!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968118e10328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278803, encodeId=cb4312e880360, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:二代测序揭示N-糖基化位点对滤泡性淋巴瘤发生发展的重要作用, objectType=article, longId=186276, objectId=466e1862e624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=466e1862e624, replyNumber=0, likeNumber=46, createdTime=2020-01-16, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=466e1862e624, moduleTitle=Blood:二代测序揭示N-糖基化位点对滤泡性淋巴瘤发生发展的重要作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=466e1862e624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278802, encodeId=d87312e8802c5, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:早期和晚期滤泡性淋巴瘤的基因表达差异, objectType=article, longId=181201, objectId=685a181201b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=685a181201b8, replyNumber=0, likeNumber=54, createdTime=2019-10-16, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=685a181201b8, moduleTitle=Blood:早期和晚期滤泡性淋巴瘤的基因表达差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=685a181201b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278801, encodeId=c2dd12e8801d3, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险, objectType=article, longId=175624, objectId=7de11e562462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7de11e562462, replyNumber=0, likeNumber=40, createdTime=2019-07-18, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7de11e562462, moduleTitle=Blood:滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7de11e562462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278800, encodeId=e76712e8800ab, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:BR治疗后早期进展与晚期滤泡性淋巴瘤的高转化风险相关, objectType=article, longId=175571, objectId=47bb1e5571e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47bb1e5571e8, replyNumber=0, likeNumber=45, createdTime=2019-07-17, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47bb1e5571e8, moduleTitle=Blood:BR治疗后早期进展与晚期滤泡性淋巴瘤的高转化风险相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47bb1e5571e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278799, encodeId=88f412e879981, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet Haematology:来那度胺联合Obinutuzumab单抗治疗复发或难治性滤泡性淋巴瘤, objectType=article, longId=175098, objectId=5aae1e5098dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae1e5098dd, replyNumber=0, likeNumber=45, createdTime=2019-07-11, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae1e5098dd, moduleTitle=Lancet Haematology:来那度胺联合Obinutuzumab单抗治疗复发或难治性滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae1e5098dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278798, encodeId=eca312e8798dd, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood cancer j:IGHV3-48基因的利用情况有望用于预测滤泡性淋巴瘤患者组织学转化的风险, objectType=article, longId=174984, objectId=d33d1e498434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d33d1e498434, replyNumber=0, likeNumber=56, createdTime=2019-07-09, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d33d1e498434, moduleTitle=Blood cancer j:IGHV3-48基因的利用情况有望用于预测滤泡性淋巴瘤患者组织学转化的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d33d1e498434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278797, encodeId=8d9112e87971d, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood:CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=37, createdTime=2019-06-28, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood:CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
滤泡性淋巴瘤
2020-05-29
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号,用以治疗滤泡性淋巴瘤(FL)
52
0
2021-02-02
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet oncol:EZH2抑制剂,有望成为滤泡性淋巴瘤患者的新选择!
65
0
2020-10-12
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤
59
0
2020-08-29
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
诺华CAR-T疗法Kymriah:达到滤泡性淋巴瘤试验终点
48
0
2020-08-07
回复
仁心济世
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤,获得FDA的突破性治疗指定
52
0
2020-07-17
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Hematol Oncol:雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达
65
0
2020-06-21
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
滤泡性淋巴瘤一线治疗将有新标准!新一代抗CD20单抗佳罗华®中国获批
50
0
2020-05-20
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
AACR 2020:伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动(PERSPECTIVE研究)
57
0
2020-05-03
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
FDA授予Kymriah治疗滤泡性淋巴瘤再生医学高级疗法(RMAT)认定
50
0
2020-04-25
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
FDA授予Umbralisib孤儿药认定,以治疗滤泡性淋巴瘤(FL)
39
0
2020-03-08
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤
45
0
2020-03-04
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
TAZVERIK(tazemetostat)治疗滤泡性淋巴瘤:FDA已批准其NDA
40
0
2020-02-17
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:局限性和晚期滤泡性淋巴瘤的基因表达差异!
52
0
2020-02-03
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:二代测序揭示N-糖基化位点对滤泡性淋巴瘤发生发展的重要作用
46
0
2020-01-16
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:早期和晚期滤泡性淋巴瘤的基因表达差异
54
0
2019-10-16
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险
40
0
2019-07-18
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:BR治疗后早期进展与晚期滤泡性淋巴瘤的高转化风险相关
45
0
2019-07-17
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Lancet Haematology:来那度胺联合Obinutuzumab单抗治疗复发或难治性滤泡性淋巴瘤
45
0
2019-07-11
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood cancer j:IGHV3-48基因的利用情况有望用于预测滤泡性淋巴瘤患者组织学转化的风险
56
0
2019-07-09
回复
gongliu
(审核中...)
关注
已关注
前往app查看评论内容
#滤泡性淋巴瘤#
Blood:CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解
37
0
2019-06-28
回复
共77条
首页
上一页
下一页
尾页
页码:
2
/4页
20条/页
扫描二维码下载梅斯医学APP
科室
订阅+
更多科室
工具
服务